Cargando…

N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells

Chronic inflammation of pancreatic islets is a key driver of β-cell damage that can lead to autoreactivity and the eventual onset of autoimmune diabetes (T1D). In the islet, elevated levels of proinflammatory cytokines induce the transcription of the inducible nitric oxide synthase (iNOS) gene, NOS2...

Descripción completa

Detalles Bibliográficos
Autores principales: Nord, Joshua A., Wynia-Smith, Sarah L., Gehant, Alyssa L., Jones Lipinski, Rachel A., Naatz, Aaron, Rioja, Inmaculada, Prinjha, Rab K., Corbett, John A., Smith, Brian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513428/
https://www.ncbi.nlm.nih.gov/pubmed/36176467
http://dx.doi.org/10.3389/fendo.2022.923925
_version_ 1784798060970246144
author Nord, Joshua A.
Wynia-Smith, Sarah L.
Gehant, Alyssa L.
Jones Lipinski, Rachel A.
Naatz, Aaron
Rioja, Inmaculada
Prinjha, Rab K.
Corbett, John A.
Smith, Brian C.
author_facet Nord, Joshua A.
Wynia-Smith, Sarah L.
Gehant, Alyssa L.
Jones Lipinski, Rachel A.
Naatz, Aaron
Rioja, Inmaculada
Prinjha, Rab K.
Corbett, John A.
Smith, Brian C.
author_sort Nord, Joshua A.
collection PubMed
description Chronic inflammation of pancreatic islets is a key driver of β-cell damage that can lead to autoreactivity and the eventual onset of autoimmune diabetes (T1D). In the islet, elevated levels of proinflammatory cytokines induce the transcription of the inducible nitric oxide synthase (iNOS) gene, NOS2, ultimately resulting in increased nitric oxide (NO). Excessive or prolonged exposure to NO causes β-cell dysfunction and failure associated with defects in mitochondrial respiration. Recent studies showed that inhibition of the bromodomain and extraterminal domain (BET) family of proteins, a druggable class of epigenetic reader proteins, prevents the onset and progression of T1D in the non-obese diabetic mouse model. We hypothesized that BET proteins co-activate transcription of cytokine-induced inflammatory gene targets in β-cells and that selective, chemotherapeutic inhibition of BET bromodomains could reduce such transcription. Here, we investigated the ability of BET bromodomain small molecule inhibitors to reduce the β-cell response to the proinflammatory cytokine interleukin 1 beta (IL-1β). BET bromodomain inhibition attenuated IL-1β-induced transcription of the inflammatory mediator NOS2 and consequent iNOS protein and NO production. Reduced NOS2 transcription is consistent with inhibition of NF-κB facilitated by disrupting the interaction of a single BET family member, BRD4, with the NF-κB subunit, p65. Using recently reported selective inhibitors of the first and second BET bromodomains, inhibition of only the first bromodomain was necessary to reduce the interaction of BRD4 with p65 in β-cells. Moreover, inhibition of the first bromodomain was sufficient to mitigate IL-1β-driven decreases in mitochondrial oxygen consumption rates and β-cell viability. By identifying a role for the interaction between BRD4 and p65 in controlling the response of β-cells to proinflammatory cytokines, we provide mechanistic information on how BET bromodomain inhibition can decrease inflammation. These studies also support the potential therapeutic application of more selective BET bromodomain inhibitors in attenuating β-cell inflammation.
format Online
Article
Text
id pubmed-9513428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95134282022-09-28 N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells Nord, Joshua A. Wynia-Smith, Sarah L. Gehant, Alyssa L. Jones Lipinski, Rachel A. Naatz, Aaron Rioja, Inmaculada Prinjha, Rab K. Corbett, John A. Smith, Brian C. Front Endocrinol (Lausanne) Endocrinology Chronic inflammation of pancreatic islets is a key driver of β-cell damage that can lead to autoreactivity and the eventual onset of autoimmune diabetes (T1D). In the islet, elevated levels of proinflammatory cytokines induce the transcription of the inducible nitric oxide synthase (iNOS) gene, NOS2, ultimately resulting in increased nitric oxide (NO). Excessive or prolonged exposure to NO causes β-cell dysfunction and failure associated with defects in mitochondrial respiration. Recent studies showed that inhibition of the bromodomain and extraterminal domain (BET) family of proteins, a druggable class of epigenetic reader proteins, prevents the onset and progression of T1D in the non-obese diabetic mouse model. We hypothesized that BET proteins co-activate transcription of cytokine-induced inflammatory gene targets in β-cells and that selective, chemotherapeutic inhibition of BET bromodomains could reduce such transcription. Here, we investigated the ability of BET bromodomain small molecule inhibitors to reduce the β-cell response to the proinflammatory cytokine interleukin 1 beta (IL-1β). BET bromodomain inhibition attenuated IL-1β-induced transcription of the inflammatory mediator NOS2 and consequent iNOS protein and NO production. Reduced NOS2 transcription is consistent with inhibition of NF-κB facilitated by disrupting the interaction of a single BET family member, BRD4, with the NF-κB subunit, p65. Using recently reported selective inhibitors of the first and second BET bromodomains, inhibition of only the first bromodomain was necessary to reduce the interaction of BRD4 with p65 in β-cells. Moreover, inhibition of the first bromodomain was sufficient to mitigate IL-1β-driven decreases in mitochondrial oxygen consumption rates and β-cell viability. By identifying a role for the interaction between BRD4 and p65 in controlling the response of β-cells to proinflammatory cytokines, we provide mechanistic information on how BET bromodomain inhibition can decrease inflammation. These studies also support the potential therapeutic application of more selective BET bromodomain inhibitors in attenuating β-cell inflammation. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513428/ /pubmed/36176467 http://dx.doi.org/10.3389/fendo.2022.923925 Text en Copyright © 2022 Nord, Wynia-Smith, Gehant, Jones Lipinski, Naatz, Rioja, Prinjha, Corbett and Smith https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Nord, Joshua A.
Wynia-Smith, Sarah L.
Gehant, Alyssa L.
Jones Lipinski, Rachel A.
Naatz, Aaron
Rioja, Inmaculada
Prinjha, Rab K.
Corbett, John A.
Smith, Brian C.
N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title_full N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title_fullStr N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title_full_unstemmed N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title_short N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
title_sort n-terminal bet bromodomain inhibitors disrupt a brd4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513428/
https://www.ncbi.nlm.nih.gov/pubmed/36176467
http://dx.doi.org/10.3389/fendo.2022.923925
work_keys_str_mv AT nordjoshuaa nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT wyniasmithsarahl nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT gehantalyssal nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT joneslipinskirachela nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT naatzaaron nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT riojainmaculada nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT prinjharabk nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT corbettjohna nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells
AT smithbrianc nterminalbetbromodomaininhibitorsdisruptabrd4p65interactionandreduceinduciblenitricoxidesynthasetranscriptioninpancreaticbcells